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mt is a great challenge to take over the responsibility of
roviding readers of the JACC with this annual review that
ighlights key contributions in the cardiovascular surgery
iterature. This task has been handled with remarkable and
nviable efficiency by Robert H. Jones, MD, over the past 5
ears. During the series, Dr. Jones altered the format from
ime to time, generally focusing on reports linking outcomes
f patients to decisions about whether an operation should
e done. Recognizing the increasing awareness of patients
egarding the “how” of surgical procedures, he also sought to
ighlight relevant data that would help practicing cardiol-
gists counsel patients regarding surgical strategy.
This year we will continue to highlight articles describing
utcomes as well as strategy in cardiovascular surgery that
racticing cardiovascular specialists will find informative
nd relevant to patient care. We have organized original
rticles around general topics, and provide insight into the
otential relevance or methodological flaws that readers
hould consider when evaluating their significance.
urgery for Valvular Heart Disease
estrictive annuloplasty and ischemic mitral regurgitation.
UNCTIONAL MITRAL STENOSIS. Dobutamine stress echo-
ardiography (DSE) and 6-min walk tests (6MWT) were
erformed in 24 patients1 year after ischemic mitral valve
epair by a strategy of downsized “restrictive” ring annulo-
lasty combined with coronary artery bypass graft surgery
CABG) (1). None of the patients had significant recur-
ence of mitral regurgitation. When compared with controls
ith coronary artery disease matched for age, sex, and left
entricular function, however, very significant differences
p  0.001) were noted in resting and stress peak mitral
alve gradients (resting: 13  4 mm Hg vs. 4  1 mm Hg;
SE: 19  6 mm Hg vs. 6  3 mm Hg) and pulmonary
rtery pressures (resting: 42  13 mm Hg vs. 27  8 mm
g; DSE: 58  12 mm Hg vs. 38  11 mm Hg). The
esting peak mitral gradient correlated with systolic pulmo-
ary artery pressures and 6MWT distance in the restrictive
rom the Department of Cardiothoracic Surgery, Mount Sinai Medical Center, New
ork, New York. Dr. Adams is a coinventor of mitral valve annuloplasty rings and has
oyalty agreements with Edwards Lifesciences. Dr. Chikwe receives royalties fromw
xford University Press. Dr. Filsoufi is a speaker for Edwards Lifesciences.
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oderate or severe ischemic mitral regurgitation for func-
ional mitral stenosis after restrictive annuloplasty (Fig. 1).
EFT VENTRICULAR REVERSE REMODELING AND IMPROVED
URVIVAL. Long-term results were reported for 108 patients
ith ischemic mitral regurgitation who underwent restric-
ive mitral annuloplasty and CABG (2). Actuarial 1-, 3-,
nd 5-year survival rates were 87  3.4%, 80  4.1%, and
1  5.1%. Pre-operative left ventricular end-diastolic
iameter (LVEDD) 65 mm was strongly associated with
oorer survival (hazard ratio: 3.4: 95% confidence interval
CI]: 1.5 to 7.4; p  0.002) (Fig. 2). Late echocardiography
as performed in all survivors (n  75), with a mean
ollow-up interval of 3.8 years (range 2.1 to 6.0 years).
itral regurgitation grade was2 in 85% of patients, and
itral stenosis was not observed (transmitral gradient mean
.9  1.7 mm Hg). In the 65 mm LVEDD group, all
urvivors showed evidence of decreased ventricular size and
everse remodeling, which contrasted with only 25% of
atients in the LVEDD 65 mm group.
OMMENT. Ischemic mitral regurgitation results from leaf-
et tethering due to papillary muscle displacement secondary
o ventricular remodeling. These studies highlight the
ebate around treating a “ventricular disease” at the mitral
nnular level. One unique feature of both studies is that
urgeons systematically downsized semirigid complete rings
nd eliminated mitral regurgitation in a durable fashion in
ost patients, in contrast to a large body of previous
iterature where surgeons utilized flexible bands or rings.
unctional mitral stenosis has not previously been reported
ith this strategy, suggesting the need for further investi-
ation. Given the paucity of data supporting a survival
enefit for surgical treatment of ischemic mitral regurgita-
ion, patients with advanced ventricular remodeling with
VEDD 65 mm should be considered for adjunctive or
lternative strategies rather than restrictive mitral annulo-
lasty and CABG alone.
hromboembolic complications after mitral surgery.
he long-term risk of ischemic stroke and bleeding was
etermined in 1,344 consecutive patients (mean age 65 
2 years) after mitral valve surgery (897 mitral valve repairs,
31 mechanical mitral valve replacements, 216 biological
itral valve replacements) (3). The rate of ischemic stroke
as lowest after mitral valve repair versus mitral valve
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Year in Cardiovascular Surgery June 23, 2009:2389–403eplacement with biologic or mechanical prostheses (6.1 
.9% vs. 8.0  2.1% and 16.1  2.7% at 5 years, respec-
ively; p  0.001) (Fig. 3). Mechanical mitral valve replace-
ent was an independent risk factor for increased long-term
leeding risk (relative risk: 2.5, 95% CI: 1.5 to 3.9), which
as reduced after mitral valve repair (relative risk: 0.39, 95%
I: 0.25 to 0.61).
OMMENT. An invited editorial brought up significant
oints, including the increased stroke risk among patients
ndergoing mitral valve surgery (including repair) during
he first 30 days after surgery compared with age-matched
Figure 1 6MWT Distance Versus Resting Mitral Peak
Transvalvular Gradient After Restrictive Annuloplasty
6MWT  6-min walk test. Modified and
reprinted with permission from Magne et al. (1).
Figure 2 Actuarial Survival After Restrictive
Annuloplasty and Pre-Operative Left Ventricular Size
Survival in 2 different pre-operative left ventricular end-diastolic diameter
(LVEDD) cohorts undergoing restrictive mitral annuloplasty and coronary artery
bypass surgery for ischemic mitral regurgitation, comparing LVEDD 65 and
65 mm (hazard ratio: 3.4; 95% confidence interval: 1.5 to 7.4; p  0.002).
Patients at risk per cohort are shown under the x-axis (LVEDD 65 mm in
bold). Reprinted with permission from Braun et al. (2).Latients: this point may have implications for the debate
ver early intervention in asymptomatic patients (4). Em-
hasis was also placed on the need to “balance” the risk of
leeding and thromboembolism during the early post-
perative period. This study re-emphasizes the importance
f documenting “late morbidity” when evaluating efficacy of
cardiac surgical procedure, and reinforces the desirability
f mitral repair over mechanical valve replacement in most
atients.
eft ventricular ejection fraction (LVEF) after surgery
or mitral valve prolapse. Post-operative echocardio-
raphic findings (mean period between surgery and echo-
ardiogram was 5  1.8 days) after mitral repair (n  779)
r mitral valve replacement (n  82) for leaflet prolapse
ere analyzed retrospectively to determine early changes in
entricular size and function (5). Although left ventricular
nd left atrial size were significantly decreased post-
peratively compared with pre-operative measurements,
VEF decreased by a mean of 8.8% (Table 1). Multivariate
nalysis identified pre-operative atrial fibrillation (AF),
dvanced New York Heart Association functional class,
reater left ventricular dimensions, lower LVEF, and larger
eft atrial size as independent predictors of a lower post-
perative LVEF.
Figure 3 Incidence of First Ischemic Stroke
After Surgery for Mitral Regurgitation
The numbers with each curve indicate the 5-year estimated rate of ischemic
stroke  SE. MRep (light solid line)  mitral valve repair; MVRb (dashed line) 
mitral valve replacement, biological; MVRm (heavy solid line)  mitral valve
replacement, mechanical. Reprinted with permission from Russo et al. (3).
chocardiographic Changes in the Earlyost-Operative Setting After Mitral Va ve Surgery
Table 1 Echocardiographic Changes in the EarlyPost-Operative Setting After Mitral Valve Surgery
Variable Pre-Operative* Post-Operative* Overall Change* p Value
LVEF, % 62.9 9.9 53.1 11.3 8.8 10.7 0.001
LVEDD, mm 69.9 7.6 53.1 7.7 7.5 7.3 0.001
LVESD, mm 36.9 7.1 36.6 8.2 0.5 6.5 0.26
Left atrial
size, mm
52.3 9.2 48.0 8.7 5.0 7.4 0.001
Expressed as mean  SD. Reprinted with permission from Suri et al. (5).
LVEDD  left ventricular end-diastolic dimension; LVEF  left ventricular ejection fraction;
VESD  left ventricular end-systolic dimension.
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June 23, 2009:2389–403 Year in Cardiovascular SurgeryOMMENT. This large series suggests that the typical patient
xperiences almost a 10% decline in LVEF during the early
ost-operative period after degenerative mitral valve repair.
o difference was observed in post-operative changes in
entricular dimensions or function between patients under-
oing chordal-sparing valve replacement and mitral repair.
o data were presented to clarify the potential recovery of
eft ventricular function in patients with decreased LVEF
mmediately after mitral surgery.
urability of mitral valve repair for degenerative disease.
he long-term durability of mitral valve repair for degenerative
isease was compared between cohorts of patients with fibro-
lastic deficiency (n 265) and Barlow’s disease (n 83) (6).
t 10 years, the freedom from reoperation was 94.4%, but the
Figure 4 Etiologic Comparison of Degenerative Mitral Valve Dis
The pathology of degenerative mitral valve disease and thus the skill required to a
chordal rupture with single segment prolapse (P1). The pathology is limited to the
ring annuloplasty (B). (C) In contrast, Barlow’s disease typically occurs in younger
excess tissue; repair techniques are more complex and include extensive resectio
Modified with permission from Adams and Anyanwu (8).
inearized Recurrence Rates (in Percent Perear) for Mitral Regurgitation After Mitral Valve Repair
Table 2 Linearized Recurrence Rates (in Percent PerYear) for Mitral Regurgitation After Mitral Valve Repair
All Patients FED Barlow
Overall 3.2 2.6 6
Without surgical risk 2.4 2.2 2.9
With surgical risk 4.7 3.6 14.9
hen only patients without surgical risk factors are included, the rates for fibroelastic disease
FED) and Barlow’s disease are similar for degenerative mitral valve repair. Reprinted with
ermission from Flameng et al. (6).reedom from mitral regurgitation more than grade 2/4 was
nly 64.9%. After accounting for surgical factors, including
onuse of annuloplasty rings in some patients, there was no
ignificant difference between the linear rate of recurrent mitral
egurgitation more than grade 2/4 for fibroelastic deficiency
ersus Barlow’s disease (2.2% vs. 2.9%, p 0.5) (Table 2). The
rimary mechanisms for recurrent mitral regurgitation were
ew leaflet prolapse, thickening, and calcification.
OMMENT. The etiologic differentiation of degenerative
itral valve disease has important implications for timing of
urgical intervention, operative strategy, and matching com-
lexity of disease to surgical expertise (7); and this paper is
he first to attempt to define outcomes according to degen-
rative mitral etiology, as opposed to leaflet involvement
e.g., bileaflet, anterior leaflet, posterior leaflet) or repair
echnique (e.g., chordal replacement or shortening, annulo-
lasty ring or suture annuloplasty). An invited editorial
ighlighted the significant pathologic and surgical differ-
nces between Barlow’s disease and fibroelastic deficiency
Fig. 4), and noted that certain patients were likely misclas-
ified as Barlow’s disease or fibroelastic deficiency, limiting
he robustness of the study (8). The observed recurrence rate
f significant mitral regurgitation suggests the need for
a successful repair varies with etiology: (A) fibroelastic deficiency resulting in
gment and the valve was easily repaired with a limited triangular resection and
ts (age 65 years) and is characterized by multisegment prolapse and marked
ular plication, sliding plasty, commissuroplasty, and large ring annuloplasty (D).ease
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Year in Cardiovascular Surgery June 23, 2009:2389–403ontinued evolution of repair techniques and supports the
rinciple of reference centers for mitral valve repair, partic-
larly for patients with Barlow’s disease.
alve replacement for low flow/low gradient aortic ste-
osis. Outcomes after aortic valve replacement were re-
orted for 217 patients with severe aortic stenosis (valve area
1 cm2), poor left ventricular function (LVEF 35%), and
ow mean aortic gradient (30 mm Hg) (9). Operative
ortality declined over the study period (20%, 1990 to
999, vs. 10%, 2000 to 2005; p 0.04). Predictors of excess
ortality included very low pre-operative mean gradient
20 mm Hg) and multivessel coronary disease. In the
ubgroup that underwent DSE (n  83), perioperative
ortality was 38% among patients without contractile
eserve versus 8% among patients with contractile reserve;
ultivessel disease and lack of contractile reserve were
ndependent predictors of perioperative mortality.
OMMENT. This retrospective study involving 11 European
enters is the largest to date analyzing outcomes in this
ifficult patient subgroup. A clear explanation for the
ecline in operative mortality in recent years was sought, but
as not obvious. Dobutamine stress echocardiography may
e a useful tool for risk stratification in this setting and may
ave been increasingly utilized in recent years. Data regard-
ng post-operative functional status and quality of life were
ot available.
ranscatheter aortic valve implantation. MANAGEMENT
ND OUTCOMES IN REFERRED PATIENTS. Experience with
05 high-risk patients referred to a transcatheter aortic valve
mplantation (TAVI) program was described (10). Thera-
Figure 5 Survival According to Treatment Strategy in High-Risk
The circles are right-censored values. Transcatheter refers to transcatheter aortic
implantation. AVR  aortic valve replacement. Reprinted with permission from Deweutic modalities included continued medical management
n  52, 49.5%), balloon aortic valvuloplasty (BAV) (n 
6, 15.2%), conventional aortic valve replacement (n  16,
5.2%), and TAVI (n  21, 20%). TAVI was limited to
elected patients meeting inclusion criteria for transcatheter
rials or compassionate use. The Society of Thoracic Sur-
eons (STS) predicted mortality risk score was greatest for
he patients who underwent BAV. The 30-day mortality
as 6.3% for conventional aortic valve replacement, 9.5%
or TAVI, 12.5% for BAV, and 13.5% for patients under
edical management. Overall mortality was highest for the
AV (37.5%) and medical management groups (42.3%)
fter average follow-up of 159  147 days (Fig. 5).
ROGRESS WITH SUCCESSIVE DEVICE GENERATIONS. A single
nstitution reported their experience with TAVI in 136
onsecutive high-risk aortic stenosis patients with successive
enerations of an aortic prosthesis (CoreValve ReValving
rosthesis, CoreValve, Irvine, California) (11). Each gen-
ration was reduced in caliber (25- to 21- to 18-F) to
acilitate vascular access and device deployment. The pro-
edural success rate (defined as stable device placement with
bsence of major adverse clinical cardiac events [MACCE],
ncluding cardiac tamponade within 24 h of the procedure)
ncreased from generation 1 and 2 versus 3 from 70.0% and
0.8% to 91.2%, respectively (p  0.003). Of note, the
eriprocedural stroke rate decreased from 10% with the
rst-generation devices to 5% with the third-generation
evice. Similarly, periprocedural mortality decreased from
0% and 8% with first- and second-generation devices to 0%
ere Aortic Stenosis
al. (10).Sev
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June 23, 2009:2389–403 Year in Cardiovascular Surgeryor the 18-F device. The 30-day mortality rate for the 18-F
evice was 10.8% (STS score predicted mortality 8.6%).
RANSAPICAL TRANSCATHETER AORTIC VALVE IMPLANTA-
ION. Initial results in a multicenter trial with transapical
AVI (Edwards Sapien Transcatheter Heart Valve, Ed-
ards Lifesciences, Irvine, California) through a small left
nterolateral thoracotomy in 40 high-risk elderly patients
mean age 83 years) were reported (12). Thirty-five of 40
alves were successfully seated; 2 valves embolized, requiring
pen retrieval; and 1 case with severe residual aortic regur-
itation required standard aortic valve replacement. Kaplan-
eier survival was 81.8  6.2% at 1 month and 71.7 
.7% at 3 months.
In another study, results with transapical TAVI (Ed-
ards Lifesciences) were described for 50 high-risk
atients with symptomatic, severe aortic stenosis in a single
enter (13). Mean patient age was 82.4  4.6 years, 39 (78%)
ere female, and the average EuroSCORE (European Sys-
em for Cardiac Operative Risk Evaluation) predicted
ortality risk was 27.6%. Cardiopulmonary bypass was
sed in 16 of 50 (32%) patients, and 3 patients required
onversion to sternotomy to deal with surgical complica-
ions. Overall survival at 30 days, 6 months, and 1 year
as 92  3.8%, 73.0  6.2%, and 71.4  6.5%,
espectively, and all patients had documented satisfactory
alve function at echocardiographic evaluation. No peri-
perative strokes were noted, and there was a trend
oward improved survival among the patients during the
atter half of the study.
OMMENT. These studies are the largest to date in the
apidly emerging field of TAVI. Initial experience cer-
ainly suggests that TAVI is a viable approach and may at
east be comparable to conventional aortic valve replace-
ent in very high risk surgical patients. Although the
esults do not match those of conventional aortic valve
eplacement, it is likely that the highest-risk patients in
urrent TAVI series would not have been accepted for
onventional surgery, so the 2 groups are not directly
omparable. There is evidence that evolving technology,
mproved patient selection, and growing procedural ex-
erience will result in improved outcomes.
icuspid regurgitant aortic valve repair. A systematic
urgical approach to valve repair was applied in 63
onsecutive patients (mean age 40  12 years) with pure
ortic valve regurgitation (unicuspid valve, n  4; bicus-
id valve, n  59) (14). A systematic segmental
orphology-specific approach was applied to bicommis-
ural aortic valve repair, taking into consideration cusp
orphology, commissural variations, and root pathology.
ne of 4 unicuspid and 41 of 59 (69%) bicuspid valves
ere initially repaired. Four patients required reoperation
or recurrent aortic regurgitation 3 (3 early and 1 at 8
onths), with 1 re-repair and 3 replacements. Early
ailures were attributed to tissue quality and fragility. A
eview of echocardiographic findings and surgical tech- iique identified cusp mobility/pliability as a predictor of
epairability.
OMMENT. An invited editorial highlighted the general
eaknesses, such as small patient numbers, limited
ollow-up, and lack of clarity as to precise criteria that
ould eliminate the option of repair, inherent in early
ioneering surgical studies (15). Nonetheless, this at-
empt to apply a “mitral repair-like” systematic lesion-
pecific approach to aortic valve repair in the setting of
solated bicuspid regurgitation is an important first step.
urgery for Coronary Artery Disease
omparison of CABG and percutaneous coronary inter-
ention. STENT VERSUS CABG FOR LEFT MAIN CORONARY
RTERY DISEASE. The early and midterm outcomes of 105
atients with unprotected left main coronary disease
andomly assigned to percutaneous coronary intervention
PCI [n  52, 35% with DES]) or CABG (n  53)
etween 2001 and 2004 were reviewed (16). The
ACCE-free 1-year survival was comparable between
CI and CABG (71.2% vs. 75.5%, respectively; p 
.29). Left main in-stent restenosis occurred in 5 pa-
ients. Four patients were treated with repeat PCI, and 1
atient underwent CABG. No early or late stent throm-
osis occurred.
In another study, the outcomes of 1,102 patients with
nprotected left main coronary disease who underwent
CI (DES, 71.1%; bare metal stent, 28.9%) and 1,138
atients who underwent CABG in 12 major cardiac
enters in Korea between January 2000 and June 2006
ere compared using propensity score matching (17). In
he overall matched cohort, there was no significant
ifference between the stenting and CABG groups in the
isk of death or the risk of composite outcome of death,
yocardial infarction (MI), and stroke (Fig. 6) during
he 3-year follow-up period. The rates of target vessel
evascularization were significantly higher in the group
hat received stents than in the group that underwent
ABG (hazard ratio: 4.76; 95% CI: 2.80 to 8.11).
OMMENT. The broader off-label application of PCI to
atients with left main coronary disease remains contro-
ersial. Left main PCI appears to be feasible, safe, and
ssociated with a high technical success rate. The rate of
ajor adverse events was similar between PCI and
ABG for left main disease after a follow-up period
veraging 3 years, suggesting it is a viable treatment
ption for high-risk patients with limited life expectancy.
he incidence of target vessel revascularization remains
igher in the PCI group; a State-of-the-Art review
ointed out that this may not come without penalty in
he long term, especially for patients with distal left main
r bifurcation lesions (18). There remains a crucial need
or data from adequately powered, prospective, random-
zed trials comparing the 2 revascularization strategies in
p
p
D
E
f
p
p
p
s
f
w
D
N
d
f
w

D
w
a
C
t
0
v
d
a
8
i
o
C
r
d
m
d
w
e
t
p
c
e
i
b
p
a
m
t
e
f
2394 Adams et al. JACC Vol. 53, No. 25, 2009
Year in Cardiovascular Surgery June 23, 2009:2389–403atients with severe multivessel disease (19). For exam-
le, the SYNTAX (Synergy Between PCI and TAXUS
ES and Cardiac Surgery) trial, first reported at the 2008
uropean Society of Cardiology meeting in Munich,
ound that DES was less effective than CABG for
reventing the 1-year primary end point of MACCE in
atients with left main and 3-vessel disease. The equi-
oise of PCI and CABG for this high-risk and complex
ubgroup remains unclear, and patients should be care-
ully informed that the evidence so far favors CABG,
ith more evidence to follow from future trials.
RUG-ELUTING STENTS VERSUS CABG IN MULTIVESSEL CORO-
ARY DISEASE. The incidence of adverse outcomes (death,
eath or MI, or repeat revascularization) was compared
or all patients with multivessel coronary artery disease
ho received DES (n  9,963) or underwent CABG (n
7,437) in New York State between October 2003 and
ecember 2004 (20). Differences in baseline risk factors
ere adjusted using a propensity model. At 18 months,
mong patients with 3-vessel disease who underwent
ABG, as compared with patients who received a stent,
he adjusted hazard ratio for death was 0.80 (95% CI:
.65 to 0.97), and the adjusted survival rate was 94.0%
ersus 92.7% (p  0.03); the adjusted hazard ratio for
eath or MI was 0.75 (95% CI: 0.63 to 0.89); and the
djusted rate of survival free from MI was 92.1% versus
9.7% (p  0.001) (Fig. 7). Similar significant differences
n survival and freedom from MI favoring CABG were
bserved among patients with 2-vessel disease.
OMMENT. This large comparative observational study of
Figure 6 Outcomes Among Patients Matched for
Propensity Scores After Left Main PCI or CABG
Outcomes for freedom from death, Q-wave myocardial infarction, or stroke.
Event-free survival rates (at 1, 2, and 3 years) were derived from paired
Kaplan-Meier curves. The solid line represents coronary artery bypass graft
surgery (CABG); the dashed line represents stenting. PCI  percutaneous
coronary intervention. Modified and reprinted with permission from Seung
et al. (17).ecent outcomes from a state-wide database with man-atory reporting (“real-world data”) indicates that CABG
ay be associated with lower midterm rates of death,
eath or MI, and repeat revascularization for patients
ith 3- and 2-vessel coronary disease. An accompanying
ditorial comments on the potential for selection bias, as
he New York Database may not capture all relevant
redictive variables, particularly those that govern physi-
ian decisions in deciding which revascularization strat-
gy to recommend (21). For example, dementia was not
ncluded in the risk-adjusted model, although it may have
iased physicians toward PCI and may be linked to worse
rognosis. During the study period, the duration of
ntiplatelet therapy was shorter than is now recom-
ended to decrease the rate of DES thrombosis, poten-
ially negatively affecting PCI outcomes. Cerebrovascular
vents were not reported in this study, and no long-term
ollow-up data are available.
Figure 7 Adjusted Curves for Long-Term
Survival and Survival Free From MI
Adjusted curves for (upper panel) long-term survival and (lower panel) survival
free from myocardial infarction (MI). The dashed lines represent coronary artery
bypass graft surgery (CABG); the solid lines represent drug-eluting stents. Sur-
vival curves were adjusted for age; sex; ejection fraction; hemodynamic state;
history or no history of MI before the procedure; presence or absence of cere-
brovascular disease, peripheral arterial disease, congestive heart failure,
chronic obstructive pulmonary disease, diabetes mellitus, and renal failure;
and involvement of the proximal left anterior descending artery. Modified and
reprinted with permission from Hannan et al. (20).
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ISEASE. The SIMA (Stenting Versus Internal Mammary
rtery Grafting) trial reported the 10-year clinical outcomes
f a cohort of 123 patients with proximal left anterior
escending artery (LAD) disease prospectively randomly
ssigned to bare-metal stenting (n  62) or single-vessel
nternal mammary artery (IMA) grafting to the LAD (n 
9) (22). At 10 years, the incidences of death and MI were
dentical at 10% in both groups; repeat revascularization
f the LAD was required in 15 patients in the PCI group
25%) compared with none in the CABG group (p 
.001), and the incidence of non-LAD revascularization
as similar, with 3 patients in each group (5%) (Table 3).
ight patients from the PCI group underwent CABG as an
dditional revascularization procedure. At 10 years, most of
he patients in both groups were either asymptomatic (93%)
r reporting mild angina (7%).
OMMENT. Very long-term outcome data comparing revas-
ularization strategies for isolated proximal LAD disease are
carce. The results suggest that CABG and PCI are
omparable, albeit with a much higher rate of repeat
evascularization within the first few years with bare-metal
CI. Drug-eluting stents might decrease the incidence of
epeat revascularization with PCI in a similar cohort, but
ata are lacking. No patient required repeat LAD reinter-
ention after IMA grafting, underlining the efficacy of this
ntervention. It is also interesting to note that, despite
ggressive statin therapy becoming prevalent only in the
ater part of the study, only 5% of patients required
ubsequent non-LAD revascularization. The risk of disease
rogression in patients undergoing isolated LAD revascu-
arization appears to be quite low.
isk modification in CABG patients. AGGRESSIVE STA-
IN THERAPY FOR PATIENTS AFTER CABG. A total of 4,654
atients with previous CABG were randomly allocated to
eceive atorvastatin 80 mg/day (n  2,316) or 10 mg/day
n  2,338) and followed up for a median of 4.9 years (23).
he primary event rate, defined as the occurrence of a major
ardiovascular event (death from coronary artery disease,
I, resuscitated cardiac arrest, or stroke) and the need for
tent Versus CABG for Proximal LAD Disease
Table 3 Stent Versus CABG for Proximal LAD Disease
Stent (n  62) CABG (n  59) p Value
Death 5 4 0.4
Cardiac death 2 1
Noncardiac death 3 3
Q-wave MI 0 1 0.9
Non–Q-wave MI 3 2
TLR 13 0 0.0001
TVR 2 0
Non-LAD PTCA 3 3
Any event 26 (42%) 10 (17%) 0.0001
eprinted with permission from Goy et al. (22).
CABG  coronary artery bypass grafting; LAD  left anterior descending; MI  myocardialr
nfarction; PTCA  percutaneous transluminal coronary angioplasty; TLR  target lesion revascu-
arization; TVR  target vessel revascularization.epeat revascularization were analyzed in this substudy of
he TNT (Treating to New Targets) trial. After CABG,
ggressive lowering of low-density lipoprotein (LDL) cho-
esterol to a mean of 79 mg/dl with atorvastatin 80 mg/dl
educed the risk of major cardiovascular events by 27%
9.7% vs. 13.0%, p  0.0004) and the need for repeat
oronary revascularization by 30% (11.3% vs. 15.9%, p 
.0001), compared with treatment with atorvastatin 10
g/dl. The safety of both regimens was comparable.
HE IMPACT OF OBESITY ON CABG PATIENTS RECEIVING
TATINS. A follow-up analysis of the Post-CABG trial was
onducted to clarify the impact of obesity on the progression
f vein graft disease and events after CABG in patients
andomly assigned to either aggressive (lovastatin 40 to 80
g/day; target LDL 60 to 80 mg/dl) or moderate (lova-
tatin 2.5 to 5 mg/day; target LDL 130 to 140 mg/dl)
holesterol-lowering therapy (24). Higher body mass index
as associated with late angiographic progression of vein
raft disease in the low-dose lovastatin group (p  0.001)
ut not in the high-dose group; no association between
igher body mass index and clinical events was observed.
OMMENT. These 2 subgroup analyzes from the TNT and
ost-CABG trials confirm that intensive LDL cholesterol-
owering treatment is associated with improved long-term
utcomes after CABG. The Post-CABG study was the first
andomized trial to document that aggressive lipid-lowering
reatment in CABG patients was associated with a decel-
ration of vein graft deterioration. The subgroup analysis
uggests that high-dose statin therapy may be protective
gainst obesity-related acceleration of vein graft atheroscle-
osis. The analysis from the TNT trial confirms that
ggressive LDL cholesterol-lowering treatment is associated
ith significant event reduction for most clinical cardiovas-
ular end points if the LDL cholesterol level is maintained
elow 80 mg/dl.
RE-OPERATIVE HEMOGLOBIN A1c AND CABG OUTCOMES. The
otential role of pre-operative hemoglobin (Hb) A1c as an
ndependent factor for adverse outcomes after primary
lective CABG was investigated in a cohort of 3,089
atients (HbA1c 7.0%, n  2,275 [74%], and HbA1c
7.0%, n  814 [26%]) using multivariate logistic regres-
ion analysis (25). An elevated HbA1c level was predictive
f hospital mortality after CABG (odds ratio [OR]: 1.40
er unit increase, p  0.02). Patients with HbA1c values of
.6% or more have adjusted odds of death 4.41 times higher
han patients with values below that threshold. Similar
hreshold values of pre-operative HbA1c appeared to pre-
ict major post-operative complications: renal failure (6.7%,
R: 2.10), cerebrovascular accident (7.6%, OR: 2.23), and
eep sternal wound infection (7.8%, OR: 5.29).
OMMENT. The impact of diabetes mellitus on early out-
ome after CABG remains controversial. Several recent
linical series have shown similar outcomes after surgical
evascularization for diabetic and nondiabetic patients with
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Year in Cardiovascular Surgery June 23, 2009:2389–403he exception of higher rates of sternal wound infection.
ther data including that from the STS database, however,
uggest that CABG in diabetic patients is associated with
ncreased post-operative mortality and morbidity. Further
tudies with significantly larger number of patients are
equired to determine whether HbA1c may be useful for
re-operative risk stratification and to determine whether
re-operative “normalization” of this marker leads to im-
roved surgical outcomes.
raft patency after CABG. A 1-year coronary angiogra-
hy follow-up study was performed on a cohort of 1,920
atients from the PREVENT IV (Project of Ex-Vivo Vein
raft Engineering via Transfection IV) trial to determine
ndependent factors associated with graft patency after
rimary on- or off-pump CABG (26). After confounding
actors were adjusted for, target artery quality, graft type and
uality, endoscopic harvest technique, and sequential graft-
ng were found to be independent predictors of vein graft
ailure defined as75% graft stenosis. The rate of vein graft
ailure was 25.3% in the on-pump group compared with
5.7% in the off-pump group (p  0.6). Poor vein graft
uality and endoscopic vein harvest were both associated
ith increased graft failure in all CABG patients and
ffected off-pump patients more than on-pump patients
OR: 1.89 and 1.78 vs. 1.09 and 1.27, respectively).
OMMENT. Several risk factors for graft failure after CABG
uch as target and graft quality, and graft type (saphenous
ein vs. internal mammary artery) are well established. A
rovocative finding in this study was that endoscopic vein
arvest, popularized during the last decade because of fewer
eg wound complications and better cosmesis, was associ-
ted with an increased rate of graft failure, particularly
mong off-pump patients. Additional studies are required to
onfirm these findings and to identify the potential injury
echanisms associated with endoscopic vein harvesting.
urgery for Advanced Heart Failure
ong-term ventricular assist device (VAD) outcomes in
he Medicare population. A retrospective analysis of
edicare claims for VAD reimbursement between 2000
nd 2006 identified 1,476 patients (mean age 63  13.4
ears) for whom a device was used as a primary therapy
nd 1,467 patients (mean age 69  10 years) who
eceived a VAD for treatment of post-cardiotomy shock
low cardiac output after heart surgery), in a total of 570
.S. hospitals (27). Of the primary device group, 65%
ere operated on in heart transplant hospitals, compared
ith only 35% in the post-cardiotomy group. More than
0% of implants were done in hospitals that did 5 of
hese operations per year, with a median volume of 1
mplant per hospital per year. The 1-year survival (with
evice, after device removal, or with transplantation) was
2% in the primary device group versus 31% in the
ost-cardiotomy group (Fig. 8). Factors associated with
orse survival included age 65 years, peripheral vascu- (ar disease, renal disease, and an annual hospital volume
f 5 implants (post-cardiotomy group only). One-year
edicare payments for inpatient care of primary device
atients and post-cardiotomy patients were $222,039,342
nd $150,887,516, respectively.
OMMENT. High mortality and costs after VAD implan-
ation in the Medicare cohort is a complex issue that is
nly partially explained by the inherent risk of this
opulation. The observation that the median volume of
mplants per hospital was 1/year is likely a major con-
ributor to the suboptimal outcomes experienced with
AD therapy in this cohort. A report this year from a
igh-volume VAD center documenting a 77% 1-year
urvival among 23 patients with a mean age of 68 years
upports the premise that higher volumes yield superior
utcomes with VAD therapy (28).
Data were not available regarding the generation of
AD implanted in the Medicare cohort, but older
rst-generation devices were likely implanted in the
ajority of patients given the time period. One can
nticipate newer generation continuous-flow devices,
hich are being increasingly utilized, will result in great
eduction in mortality and morbidity associated with
AD therapy. For example, another high-volume center
his year reported an 87% 6-month survival among 47
atients who received second-generation axial flow-
umps between 2005 and 2007 (29). The notably poor
utcome for post-cardiotomy elderly Medicare patients,
oupled with the high costs, raises an economic and
thical debate as to the allocation of health care resources
o VAD therapy for this subgroup.
yoblast transplantation. Initial results of the MAGIC
Figure 8
Long-Term Survival Among
Medicare Beneficiaries Who Received
a Ventricular Assist Device, 2000 to 2006
Error bars indicate 95% confidence intervals. Modified
and reprinted with permission from Hernandez et al. (27).Myoblast Autologous Grafting in Ischemic Cardiomy-
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June 23, 2009:2389–403 Year in Cardiovascular Surgerypathy) trial were reported (30). One hundred twenty
atients with ischemic cardiomyopathy undergoing
ABG were randomly allocated to injection of either
ow-dose (n  33) or high-dose (n  30) autologous
keletal myoblast cells or placebo (n  34) into akinetic,
onrevascularized myocardium (23 patients did not re-
eive assigned intervention). Myoblast injections did not
ield any difference in primary end points (global and
egional left ventricular function at 6 months) in the
reatment arms compared with the control arm (Fig. 9).
here was also no difference in the New York Heart
ssociation functional class or quality of life among the 3
roups. There was no significant increase in incidence of
ajor adverse events in the intervention group. There
as a trend toward a decrease in left ventricular size, but
lso a higher incidence of ventricular arrhythmias, in the
igh-dose treatment arm.
OMMENT. A “Clinical Perspective” published with this
rticle (30) highlighted the significant points learned
rom this rigorous randomized, prospective, double-
linded study: 1) implanted myoblasts may increase
aracrine signaling; 2) it remains suspect that there is any
ositive impact on patient outcomes; and 3) further
ptimization of the “best cells,” their method of delivery,
nd strategies enabling the enhancement of graft survival
nd functional integration remain to be defined.
ost-infarction cardiogenic shock—role of CABG. Data
rom the STS database for 14,956 patients reported to
ave been in cardiogenic shock at the time of CABG
urgery were analyzed (31). During the study period
2002 to 2005), patients in cardiogenic shock represented
.1% of patients in the STS database undergoing CABG,
Figure 9 6-Month Change From Baseline in LVEF After Myoblas
Data are given as median and interquartile range. The pooled treatment groups an
a Wilcoxon test. The associated probability value was 0.62 for left ventricular ejecut accounted for 14% of all CABG deaths. Operative
ortality was 20% for isolated CABG procedures, and
he mortality was highest if the patient underwent
urgery within 24 h of MI (26%). Mortality decreased to
0% if patients underwent CABG 1 to 21 days after MI,
nd fell to 18% if surgery took place 21 days later.
ortality was higher when concurrent procedures were
erformed, rising to 33% for CABG plus valve surgery,
nd to 58% for CABG plus ventricular septal defect
epair (Fig. 10). Less than 3% of cardiogenic shock
atients received ventricular assist devices.
OMMENT. CABG as treatment for cardiogenic shock com-
licating MI remains associated with a high early mortality
ate. A simple bedside risk score was also presented that
ccurately stratified patients into those with low (10%) to
ery high (60%) mortality. The highest risk subgroups
ay benefit from wider application of newer generation
emporary ventricular assist devices.
ardiac transplantation—expanding the donor pool. Do-
or left ventricular hypertrophy and donor cocaine use are
elative contraindications to heart donation. In a retro-
pective review of 427 heart transplants performed with
earts from donors without (n  365) or with (n  62)
eft ventricular hypertrophy (classified based on septal or
osterior wall thickness as mild, 1.2 to 1.3 cm, n  26;
oderate, 1.4 to 1.7 cm, n  33; or severe, 1.7 cm, n
3), there was no significant difference in 1-year (97%
s. 91%, p  0.2) or 5-year (84% vs. 70%, p  0.07)
urvival (32). Regression of left ventricular hypertrophy
n the transplanted hearts was observed over time under
ailored medical therapy.
nsplantation
placebo group were compared with
ction (LVEF). Modified with permission from Menasche et al. (30).t Tra
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Year in Cardiovascular Surgery June 23, 2009:2389–403A retrospective analysis of data from the United Network
f Organ Sharing registry compared data on 931 transplants
rom donors with a history of cocaine abuse with those of
,006 transplants in which the donor was never known to
ave used cocaine and found a similar 1-year survival
egardless of whether the donor was a current (86%), past
89%), or nonuser (86%) of cocaine (33). Similar survival
ates existed after adjustment for known risk factors.
OMMENT. Broadening of the donor pool to include donors
egardless of past or current cocaine use seems to be safe.
onors with left ventricular hypertrophy can also be safely
ransplanted, but collaborative registry data would strengthen
his concept. Some caution may be warranted—for example,
Figure 10 In-Hospital Death Among Patients With Cardiogenic
Cardiac surgery included coronary artery bypass graft surgery (CABG), aortic valve
ture (VSR) repair and CABG. The mortality rate of patients with cardiogenic shock
were not in cardiogenic shock (beige bars) from The Society for Thoracic Surgeonso patients with left ventricular hypertrophy in the currently gnalyzed cohort had long ischemic times (240 min), so it
ay still be necessary to tailor decision making to use such
onor hearts, based on available data.
ortic Surgery
ndovascular repair of thoracic aneurysms. Results of a
hase 2 multicenter study involving 140 patients with
escending thoracic aneurysms treated by endovascular
tent grafting between 1999 and 2001 was reported, with
4 nonrandomized patients undergoing surgical repair
cting as a control group (34). At 5 years, aneurysm-
elated mortality was lower for the endovascular stent
k Undergoing Cardiac Surgery
y (AV) and CABG, mitral valve surgery (MV) and CABG, and ventricular septal rup-
ars) was compared with that of patients undergoing similar procedures who
) database. Reprinted with permission from Mehta et al. (31).Shoc
surger
(blue b
(STSroup compared with the control group (2.8% vs. 11.7%,
p
T
5
s
e
d
i
r
a
3
(
v
t
s
C
t
b
s
m
f
o
(
a
f
c
d
u
A
S
1
t
b
m
1
w
d
(
r
p
r
t
t
c
c
o
o
a
w
a
t
C
r
b
b
t
e
a
a
d
o
o
w
2399JACC Vol. 53, No. 25, 2009 Adams et al.
June 23, 2009:2389–403 Year in Cardiovascular Surgery 0.008) because of improved perioperative survival.
he incidence of major adverse events, including death at
years, was also significantly lower in the endovascular
tent group, reflecting an early reduction in major adverse
vents (Fig. 11). There was no statistically significant
ifference between groups for death from all causes.
Another single center reported a retrospective compar-
son between 352 endovascular repairs and 372 surgical
epairs of descending thoracic and thoracoabdominal
neurysms operated on between 2001 and 2006 (35). The
0-day (5.7% vs. 8.3%, p  0.2) and 1-year mortality
15.6% vs. 15.9%, p  0.9) were similar between endo-
ascular and surgical groups, respectively. There was a
rend toward more spinal cord ischemic events in the
urgical cohort (7.5% vs. 4.3%, p  0.08).
OMMENT. The primary limitation of these studies is
heir nonrandomized nature, and resultant differences
etween treatment groups. In the latter study (35),
tented patients were on average 9 years older and had
ore comorbidities. The multicenter study also suffered
rom incomplete follow-up, with more than one-quarter
f patients lost to or refusing follow-up during the trial
34). It appears that endografting of descending thoracic
ortic aneurysms is a safe and effective method of repair
or anatomically suitable lesions, with immediate results
omparable to those of open surgical repair. Results and
urability for this procedure beyond 5 years are still
Figure 11 Freedom From Major AE (Including
Death) Over Time After Aortic Stenting or Surgery
Major adverse events (AE), including death, were significantly lower among
patients undergoing endovascular aortic stenting of descending thoracic aortic
aneurysms (TAG cohort [solid line]) than among patients undergoing conven-
tional open repair (surgical controls [dotted line]), primarily because of a
reduction in perioperative adverse outcomes. Modified and reprinted with per-
mission from Makaroun et al. (34).nknown.trial Fibrillation
urgery for AF at the time of mitral surgery. Data from
0 U.S. and European centers participating in an interna-
ional registry were analyzed to determine the clinical
enefit of concomitant AF surgery in patients undergoing
itral valve surgery (36). Patients with follow-up of at least
year (n  972) were divided into 3 groups based on
hether they were in stable sinus rhythm (sinus rhythm
ocumented at all follow-up visits within 1 year), stable AF
AF documented at all follow-up visits), or an unstable
hythm (all other rhythms). At the time of surgery,70% of
atients were considered to have permanent AF, with the
emainder either in paroxysmal or persistent AF. Surgical
echniques to treat AF varied according to the discretion of
he surgeon and included different energy sources and
ut-and-sew techniques. The cut-and-sew type maze pro-
edure was found to be an independent risk factor for
perative mortality (OR: 8.92, p  0.009). At 1 year, 66%
f patients were in stable sinus rhythm, which was
ssociated with higher early and late survival compared
ith stable AF and other rhythms (p  0.01, log-rank
nalysis) (Fig. 12), as well as greater freedom from
hromboembolic events (p  0.01, log-rank analysis).
OMMENT. This study was based on data from a voluntary
egistry, which is inherently prone to selection and reporting
ias. Lesion sets were described as “maze III, non-maze
iatrial, left side only, and right side only,” but each of these
erms covers a wide spectrum of surgical strategies and
fficacy, and without better standardization, it is difficult to
ssess whether the relatively low reported freedom from AF
t 1 year was due to suboptimal surgical techniques. The
ata are further compromised by the lack of standardization
f follow-up protocols. Holter monitoring was used largely
n an ad hoc basis. Another confounder not accounted for
as the type of mitral surgery: no data were presented on
Figure 12 Actuarial Survival After Atrial
Fibrillation/Mitral Surgery According to Rhythm
Patients in stable sinus rhythm (sSR [blue line]) 1 year after mitral surgery
experienced significantly better long-term survival than did patients who were in
stable atrial fibrillation (sAF [yellow line]) or any other rhythm (Other [red line]).
Reprinted with permission from Melo et al. (36).
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Year in Cardiovascular Surgery June 23, 2009:2389–403hether patients underwent valve replacement or repair, but
ince 50% of patients were noted to have rheumatic
isease, one can assume a high proportion of patients
eceived mechanical valves, which present an additional
urden of risk for events (3). Nonetheless, these data
mphasizes the importance of continued efforts to develop
trategies for AF in the setting of mitral valve disease.
trial fibrillation after CABG. A prospective observa-
ional study of 1,832 patients undergoing CABG was
onducted to determine the impact of post-operative AF on
urvival (37). Atrial fibrillation developed in a total of 570
31%) patients. Compared with patients who did not have
ost-operative AF, hospital mortality (3.3% vs. 0.5%, re-
pectively; p  0.001) and late mortality (2.99 of 100
erson-years vs. 1.34 of 100 person-years, respectively;
djusted hazard ratio: 2.13, p  0.001) were increased in
atients with post-operative AF. After adjustment for
onfounding variables, post-operative AF was found to
ncrease the risk of cardiac mortality threefold, and quadru-
led the risk of clinically significant embolic events.
OMMENT. This study is limited by its observational nature,
eliance on self-reporting of post-operative arrhythmias,
ack of data about the duration of AF, and lack of standard-
zed protocols for rhythm management and anticoagulant
herapy and monitoring. While the data reinforce the
ikelihood that post-operative AF after CABG is indepen-
ently associated with mortality, the degree to which AF is
cause of the excess mortality as opposed to a marker of
usceptibility for death cannot be determined. Further study
s required to determine whether measures to prevent AF
ranslate into reduced CABG mortality.
eft atrial appendage closure. A retrospective analysis of
37 patients who underwent transesophageal echocardiog-
aphy after surgical closure of the left atrial appendage was
erformed to determine the success of atrial appendage
losure techniques (38). Techniques included excision
38%), internal suture of the orifice from the left atrium
53%), and stapler exclusion (9%). Successful closure of the
eft atrial appendage occurred in 73% of patients after
xcision versus 23% with suture and 0% with staple exclu-
ion (p  0.001). Left atrial thrombus was common (41%)
n patients with failed attempted closure of the left atrial
ppendage.
OMMENT. It is somewhat surprising that only 40% of
atients in the study had successful obliteration of the left
trial appendage. The data may not be representative in that
he 137-patient cohort, selected on the basis of a post-
perative transesophageal echocardiography study, repre-
ented a small sample of the overall cohort (n  2,546) who
ad left atrial appendage closure during the study period at
his institution. Although excision was more successful than
xclusion techniques, this approach may not be applicable to
ll patients, such as patients undergoing reoperation and
lderly patients with fragile tissue. Although stapling tech-
iques are particularly attractive in minimally invasive ap- uroaches to AF surgery, this study suggests they are largely
neffective, possibly because the stapler cannot generally be
pplied down to the true base of the appendage. There is a
eed for further research into alternative strategies to
xclude the left atrial appendage (39); decision making
egarding anticoagulation therapy management and the
afety of cardioversion in the post-operative setting should
ot be altered unless an imaging study has confirmed the
uccess of a surgical left atrial appendage closure procedure.
inimally Invasive Surgery
obotic mitral valve repair. A series of 300 patients who
eceived robotic mitral valve repair, constituting 32% of all
itral valve operations at a single institution between 2000
nd 2006, was reported (40). Robotic exclusion criteria
ncluded extensive mitral annular calcification, anticipated
itral valve replacement, severe pulmonary hypertension,
oor left ventricular function (ejection fraction 20%), and
ignificant coronary artery disease. Early complications in-
luded 2 operative deaths (0.7%), 2 strokes (0.7%), and 3
Is (1.0%). Mean length of hospital stay was 5.2 days. At
mean follow-up of 815 days, echocardiography in 279
atients showed none, trivial, or mild regurgitation in 258
92.4%); moderate in 15 (5.4%); and severe in 6 (2.2%).
ive-year survival and freedom from reoperation were
6.6% and 93.8%, respectively.
OMMENT. This is the largest series to date demonstrating
he safety and efficacy of robotic mitral valve repair per-
ormed on well-selected patients in a high-volume center.
actors contributing to the low penetration of robotic heart
urgery include complexity of the technique, lack of appli-
ability to the majority of patients needing heart surgery,
ogistic complexities involved in its set-up, prolonged oper-
tive times, high level of skill and training required to do the
rocedures, lack of definite evidence of benefit, availability
f alternative conventional surgical techniques that are safe
nd at least as effective, and high costs (set-up costs are as
igh as $1 million U.S. dollars, and additional costs of
isposables per case are as high as $2,000 U.S. dollars). One
f the key expected economic benefits of robotic heart
urgery—reduced hospital length of stay—does not appear
o have materialized.
ransfusion and Coagulation
ed cell storage and complications after cardiac surgery.
he outcomes of 2,872 patients undergoing CABG, valvu-
ar heart surgery, or both, between 1998 and 2006, who
eceived 8,802 units of blood that had been stored for 14
ays or less were compared, using propensity analysis, to the
utcomes of 3,130 patients receiving 10,782 units of blood
hat had been stored for 14 days (41). The 2,364 patients
ho received a mix of newer and older blood were excluded
rom the analysis. The distribution of the number of red cell
nits transfused per patient was similar in both groups.
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June 23, 2009:2389–403 Year in Cardiovascular Surgeryatients given older blood had higher in-hospital mortality
2.8% vs. 1.7%, p  0.004), and higher incidences of
espiratory failure (9.7% vs. 5.6%, p  0.001), renal failure
2.7% vs. 1.6%, p  0.003), and sepsis (4.0% vs. 2.8%, p 
.01). Midterm survival was significantly lower for patients
iven older blood (Fig. 13).
OMMENT. The major finding of this study was that trans-
usion of red cells stored for 2 weeks increased the relative
isk of post-operative death by 30%, as well as the risk of
ajor perioperative morbidity. Although it may be imprac-
ical to classify blood as outdated earlier than current
ecommendations, this study certainly suggests the need for
urther investigation as well as possible alterations in blood-
anking procedure and policy to limit potential harm to
atients from the use of older blood.
isk of anemia in cardiac surgery. The outcomes of 774
atients with mild to moderate anemia (defined as hemo-
lobin between 9.5 and 12.5 g/dl) who underwent elective
ardiac surgery during 2004 at 7 institutions were compared
ith those of 2,512 patients without anemia who underwent
ardiac surgery during the same period (42). Propensity
atched outcomes analysis was applied to 515 pairs. The
isk-adjusted OR obtained by propensity score matching for
he composite outcome of in-hospital death, stroke, or acute
Figure 13 Kaplan-Meier Estimates of Survival and Death After
Patients receiving blood exclusively older than 14 days (blue circles and lines) ha
significantly poorer survival at 1 and 2 years after cardiac surgery than did patient
Solid lines represent estimated survival or the rate of death. Dashed lines represe
graph refer to the patients at risk. Reprinted with permission from Koch et al. (41enal failure in patients with anemia was 1.8 (95% CI: 1.2 to o.7, p  0.005) when compared with patients without
re-operative anemia.
OMMENT. In this analysis, even after adjusting for comor-
idities and intraoperative blood transfusion, anemia (which
ad a prevalence of 25% in elective cardiac surgical
atients in this cohort), appeared to be an independent risk
actor for major adverse post-operative outcomes. Because
f the retrospective nature of the study, and because neither
he cause nor the duration of pre-operative anemia was
escribed, it is impossible to determine whether anemia was
marker for severity of underlying and occult disease rather
han a direct cause of adverse outcome. There were no
ollow-up data beyond the initial hospitalization.
protinin in cardiac surgery. The post-operative out-
omes of 1,343 patients undergoing CABG with or without
oncomitant valve surgery between 1996 and 2005, and who
eceived aprotinin, were compared with those of 6,776
atients who received aminocaproic acid and 2,029 patients
ho received no antifibrinolytic therapy (43). The mortality
ate in the aprotinin group was 6.4%, compared with 2.4%
n the aminocaproic acid group, and 2.2% for the group
eceiving no antifibrinolytic agent; after risk adjustment, the
azard ratio for death of patients treated with aprotinin
ompared with patients receiving no antifibrinolytic therapy
fusion of Older or Newer Blood
her rate of death during the early post-operative period (inset) and experienced
received exclusively blood that was 14 days old (yellow circles and lines).
% confidence intervals. The numbers above and below the circles on the mainTrans
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o 1.46, p  0.004), respectively. Aprotinin use was also
ssociated with a larger risk-adjusted increase in serum
reatinine (p  0.0001).
Another retrospective database study published simulta-
eously reported a relative risk of in-hospital death of 1.32
95% CI: 1.08 to 1.63) in a propensity score matched
nalysis of 33,517 patients receiving aprotinin during
ABG compared with 44,682 who did not (44).
The BART (Blood Conservation Using Antifibrinolytics
rial) investigators subsequently published the results of
heir prospective randomized trial of aprotinin and lysine
nalogues in cardiac surgery, with similar findings (45).
assive bleeding was less common in the aprotinin group,
ut at the expense of increased mortality, as the relative risk
f death compared with patients receiving lysine analogues
as 1.53 (95% CI: 1.06 to 2.22). The study was terminated
efore completion by the Data Safety Monitoring Commit-
ee, on the basis of their interim data analysis of 2,163
atients.
OMMENT. Bayer suspended marketing of aprotinin after
he decision by the BART investigators to suspend their
rial, and the Food and Drug Administration issued a
rug recall. A surgical editorial suggested that surgeons
ere partly responsible for the demise of aprotinin
ecause of uncontrolled use and overwhelming bias to-
ard its benefit (46).
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